Cita APA

Basso, M., Strippoli, A., Orlandi, A., Martini, M., Calegari, M. A., Schinzari, G., . . . Barone, C. (2013). KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients. Nature Publishing Group.

Chicago Style Citation

Basso, M., et al. KRAS Mutational Status Affects Oxaliplatin-based Chemotherapy Independently From Basal MRNA ERCC-1 Expression in Metastatic Colorectal Cancer Patients. Nature Publishing Group, 2013.

Cita MLA

Basso, M., et al. KRAS Mutational Status Affects Oxaliplatin-based Chemotherapy Independently From Basal MRNA ERCC-1 Expression in Metastatic Colorectal Cancer Patients. Nature Publishing Group, 2013.